Non-rheumatic atrial fibrillation and stroke

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Non-rheumatic atrial fibrillation (NRAF) carries a substantial risk of systemic embolism and stroke.
• Annual embolic rates in NRAF patients are around 5%, potentially reaching 20% in those with left atrial enlargement, left ventricular dysfunction, or prior embolism.

Purpose of the Study:

• To emphasize the need for individualized patient management in NRAF.
• To highlight the importance of risk stratification using clinical and echocardiographic features.
• To discuss the benefits and risks of anticoagulation, particularly warfarin, versus aspirin.

Main Methods:

• Review of clinical markers associated with increased embolic risk in NRAF.
• Evaluation of transthoracic echocardiography (TTE) for risk stratification.
• Consideration of transesophageal echocardiography (TEE) for selected patients.
• Analysis of randomized trial data comparing warfarin and aspirin efficacy.

Main Results:

• Clinical risk factors include older age, prior embolism, heart failure, hypertension, and diabetes.
• TTE identifies higher embolic risk with left atrial dilation, atrial dysfunction, and LV dysfunction.
• Warfarin generally demonstrates greater benefit than aspirin in randomized trials.
• Increasing age may not significantly increase warfarin-related bleeding risk.

Conclusions:

• Individualized stroke prophylaxis decisions are essential for NRAF patients.
• Echocardiography significantly aids in refining embolic risk assessment.
• Warfarin is often more beneficial than aspirin, especially in older patients.
• A target INR of 2.0-3.0 is suggested for patients treated with warfarin.